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Abstract
Background: Previous studies indicate that sumatriptan is not effective when second messenger levels are high as
after cilostazol provocation. Therefore, we have conducted the present study, where sumatriptan is administrated as
pretreatment before cAMP increases due to cilostazol intake. Our hypothesis was that pretreatment with
sumatriptan would have a significant effect against cilostazol induced headache in healthy volunteers.
Methods: In a double-blind, randomized, crossover design, 30 healthy volunteers of both sexes received cilostazol
200 mg on two separate days, each day preceded by oral sumatriptan (2 × 50 mg) or placebo. Headache response
and accompanying symptoms were registered in a questionnaire by the participants themselves.
Results: Cilostazol induced a mild to moderate headache in all but 3 participants (Range 0–7 on Numerical Rating
Scale). There was no significant difference in headache score 2 h (p = 0.67) or 4 h (p = 0.1) after treatment between
the 2 days. Median peak headache score was 1.5 (range 0–5) on the sumatriptan day and 2 (range 0–7) on the
placebo day (p = 0.26).
Conclusion: Pre-treatment with sumatriptan prevents cilostazol induced headache from developing. However, the
placebo group did not develop enough headache to get statistical significant results. The cilostazol pre-treatment
model is valuable for experimental headache research and perhaps for testing drugs with another mechanism of
action.
Trial registration: ClinicalTrials.gov Identifier: NCT03156920.
Keywords: Headache, Migraine, Pain, Phosphodiesterase type 3, Human migraine model
Background
In recent years, the authors made a dedicated attempt to
develop a pragmatic model for testing new anti-migraine
drugs. The idea behind the model is to have participants
come to the hospital and to be able to induce migraine
attacks and treat them. That would enable the drug
industry to test their new anti-migraine drug under con-
trolled conditions, inexpensively and in a short period of
time. We have tried to develop the model in both
healthy volunteers and in patients with migraine without
aura (MO) using two different headache inducing
substances; Isosorbide-5-mononitrate (5-ISMN, a long
lasting NO-donor) and cilostazol (a phosphodiesterase
3- inhibitor).
NO leads to an increase in cGMP in the cell and
cilostazol increases cAMP [1, 2]. To validate the model,
we tested the effect of sumatriptan on the induced head-
ache. Sumatriptan had no effect on 5-ISMN induced
headache [3]. When treating cilostazol induced headache
in healthy volunteers with sumatriptan, we saw a trend
towards an effect [4] and the trend was stronger when
the same study was conducted in MO patients [5].
However, all three studies indicate that sumatriptan is
not effective when second messenger levels (cGMP and
cAMP), are increased in the system. Therefore, we have
conducted the present study, where sumatriptan is
administrated as pretreatment before cAMP increases
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due to cilostazol intake. Our hypothesis was that pre-
treatment with sumatriptan would have a significant
effect against cilostazol induced headache in healthy
volunteers.
Methods
A similar method has been described previously in three
studies by the authors [3–5].
Participants
Thirty healthy volunteers (15F/15M) with no history of
migraine were included. Inclusion criteria were: healthy
subjects of both sexes aged 18–60 years and weighting
45–90 kg.
Exclusion criteria were: any type of headache (except
episodic tension-type headache < 1 day per week),
serious somatic or psychiatric disease, pregnancy, and
intake of daily medication (except oral contraceptives).
The participants were informed that cilostazol might
induce headache or migraine in some individuals.
Design
We conducted a double-blinded, randomized, balanced,
placebo-controlled, cross-over study. The participants
received pre-treatment with 50 mg of sumatriptan or
placebo 1.5 h prior to oral cilostazol of 200 mg.
Together with cilostazol intake, the participants took an
additional 50 mg of sumatriptan or placebo. Tmax for
both sumatriptan and cilostazol is about 2 h and we thus
reach maximum concentration of sumatriptan and
cilostazol at the same time. The reason why we also gave
sumatriptan 1.5 h prior to cilostazol was to have a
high dose of sumatriptan at time of cilostazol intake.
Cilostazol dose (200 mg) was chosen based on previous
headache-studies.
The central pharmacy of the Capital Region of
Copenhagen performed the randomization of the experi-
mental drug in a balanced fashion. The randomization
code did not leave the hospital during the study and was
not available to the investigators until after termination
of the study. We did not break the code until data
management took place.
Standard protocol approvals
All participants gave written, informed consent to
participate in the study. The study was approved by the
Ethics Committee of Copenhagen (H-15011960) and the
Danish Data Protection Agency. The study is registered
on clinicaltrials.gov (NCT03156920) and was conducted
according to the Helsinki II declaration of 1964, as
revised in 2008.
All participants were enrolled via the website for-
søgsperson.dk [6].
Study procedure
The participants had to be headache free 48 h prior to
the study and not to have taken any type of painkillers
12 h before beginning of the study. A pregnancy test
was taken at the beginning of each study day on all
fertile female participants. All participants had two
separate study days at least five days apart. They arrived
non-fasting at the clinic between 8:00 a.m. and
12:00 p.m. Full medical history, physical examination,
electrocardiography (ECG), vital signs and baseline
headache were collected at arrival. All participants
received the treatment (placebo or sumatriptan) and
waited for 1.5 h before they received cilostazol 200 mg
orally together with an additional pill of treatment (the
same treatment as the first one). Hereafter the partici-
pants were discharged from hospital. In case of severe
headache not responding to the experimental treatment,
the participants were allowed rescue with nonsteroidal
anti-inflammatory drugs (NSAIDs) and paracetamol, but
not before two hours after cilostazol. During the study,
an emergency phone was always open where participants
could call if they experienced severe headaches or
discomfort.
Headache parameters
Headache parameters and accompanying symptoms
were recorded by the investigator at baseline on a head-
ache questionnaire. Afterward headache intensity, char-
acteristics (unilateral/bilateral, quality and aggravation
by physical activity), accompanying symptoms (nausea/
vomiting, phono- and photophobia) and side effects
were scored on a self-administered questionnaire. The
participants had to fill out the questionnaire every
30 min the first 6 h after cilostazol and thereafter every
hour until 12 h after cilostazol. The intensity was scored
on a Numerical Rating Scale (NRS) from 0 to 10, 1
representing a very mild headache (including feeling of
pressing or pulsation), 5 a headache of medium severity
and 10 the worst possible headache (10). Missing data
were filled in using last observation carried forward.
The following criterion was used for a migraine-like
attack induced 0–12 h after administration of cilostazol:
Headache fulfilling criteria C and D for migraine
without aura according to the IHS criteria [7].
C. Headache has at least two of the following
characteristics:
 Unilateral location
 Pulsating quality
 Moderate or severe pain intensity (moderate to
severe pain intensity is considered ≥4 on NRS)
 Aggravation by cough or causing avoidance of
routine physical activity
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D. During headache at least one of the following:
 Nausea and/or vomiting
 Photophobia and phonophobia.
Statistical analysis
Calculation of sample size was based on the detection of
a difference in headache intensity between two experi-
mental days, at 5% significance with 90% power. We es-
timated that placebo had an effect on 20% and
sumatriptan had 60% effect. Standard deviation was
estimated based on previous data. The correlation
between the 2 days was estimated conservatively at 0.5.
We also assumed no carry-over effect. We calculated
that at least 18 participants should complete both
experimental days. Due to uncertainty regarding these
assumptions we decided to include 30 participants. The
area under the curve (AUC) for headache score was used
as a summary measure for analyzing differences between
the groups and was calculated according to the trapez-
ium rule (12). Our primary endpoints were (1) difference
in pain intensity difference between sumatriptan and
placebo 2 hours after the last treatment, and (2) differ-
ence in AUC 0-4 h between the two experimental days.
Secondary end-points were difference in median peak
headache score, difference in median headache intensity
between the two treatments at 4 h, AUC 0-2 h after
sumatriptan/placebo and accompanying symptoms as
nausea, photo- and photophobia.
Headache intensity scores are presented as medians
(range). Differences in AUC for headache scores were
tested using the Wilcoxon signed rank test. Difference in
pain intensity difference between the sumatriptan day
and the placebo day were tested using Mann-Whitney
test. The incidence of headache and associated symp-
toms were analyzed as binary categorical data with
McNemar’s test. Age and weigh are presented as means.
All analyses were performed with SPSS for Windows
11.5 (Chicago, IL, USA), or GraphPad Prism version 7.0.
A p < 0.05 was considered significant.
Results
Thirty participants (15F, 15 M) with a mean age of 26.5
(19–58 years) and a mean weight on 71.6 kg (48-93 kg),
completed the study. Three participants had a first
degree relative with migraine (self-reported).
Cilostazol induced a mild to moderate headache
(range 1–7 on NRS) in all but three participants. The
headache had some migraine features, especially throb-
bing character and it was aggravated by physical activity
(see Table 1 for clinical characteristics of the headache
and associated symptoms). Median peak headache score
was 1.5 (range 0–5) on the sumatriptan day and 2 (range
0–7) on the placebo day. Median time to peak headache
score was 5 h and 4.5 h respectively. Two subjects in
each group experienced a migraine-like attack with a
mean time of onset of 8.5 h (7 and 10 h) on the suma-
triptan day and 4 h (1 and 7 h) on the placebo day.
There was no significant difference in headache score
between the 2 days at 2 h after treatment (p = 0.52) and
thus our primary end-point was negative. Two hours
after treatment intake, median headache score was 0
(range 0–3) for the sumatriptan day and 1 (range 0–4)
for the placebo day. At 4 h after treatment intake (our
secondary end-point) there was no significant difference
either (p = 0.06). Median headache score 0-12 h after
cilostazol for the two treatment groups is illustrated in
Table 1 Clinical characteristics (our secondary end-point) of headache and associated symptoms after cilostazol
Sumatriptan (n = 30) Placebo (n = 30) P-value*
Number of participants reported headache 27 27 1.00
(range 1–7 on VRS)
Median peak headache score (range) 1.5 (0–5) 2 (0–7) 0.26**
No. of participants with
Throbbing headache 13 15 0.77
Unilateral location 10 8 0.77
Nausea 7 6*** 1.00
Aggravation by physical activity 15 17 0.79
Photophobia 7 5 0.72
Phonophobia 4 2 0.61
Rescue medication 0 2 0.48
Migraine-like attack 2 2 1.00
* McNemar’s test
** Wilcoxon signed rank test
*** Two subject vomited
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Fig. 1 and headache score after treatment is illustrated in
Fig. 2.
Our other primary end point, AUC 0-4 h after treat-
ment did not differ between the 2 days (p = 0.57). Nor
did we see a difference in our secondary end point,
difference in peak headache score (p = 0.26) see Fig. 3.
Discussion
Cilostazol induced a mild to moderate headache in 27/
30 participants. The median headache score after suma-
triptan was 0 and thus sumatriptan may have prevented
the headache from developing. However, our end-points
were all statistically negative because the placebo group
did not develop much headache either (median headache
score at 1) (See Fig. 1).
Modifying the model from previous studies
In previous studies, we showed a trend towards an effect
of sumatriptan on cilostazol induced headache in both
healthy volunteers and in MO patients [2, 3]. The effect
was, however, not clear and the model needed modifica-
tion in order to be valid for future drug testing. Cilosta-
zol induces headache by an increase of cAMP which
leads to vasodilatation and sensitization of nerve endings.
One possible explanation for the lack of effect of suma-
triptan in our previous studies could be that sumatriptan
cannot exert its effect when cGMP and cAMP have
already accumulated in the cell, which happens after
provocation with isosorbide-5-mononitrate and cilostazol
respectively [1–3].
Cilostazol inhibits phosphodiesterase 3 and thus pre-
vents cAMP break-down. Therefore, in order for cAMP
to be accumulated in the cell due to cilostazol, there
must be cAMP in the cell beforehand. Sumatriptan
inhibits adenylate cyclase leading to a decreased forma-
tion of cAMP in the cell. In the present study we tried
to modify the previous model by administering suma-
triptan as pretreatment and thus impeding the formation
of cAMP before cilostazol provocation. We hypothesized
that there would be no cAMP to accumulate in the cell
and therefore no headache would occur. Our results
suggest that sumatriptan pre-treatment may prevent the
headache from developing since median headache score
remained 0 until 6 h after sumatriptan. At 6 h the effect
of sumatriptan has subsided and the headache score
increased to 1, like in the placebo group (see Fig. 1). An
explanation why our results all came out statistically
negative is that we have a considerably lower headache
induction in the present study, compared to previous
studies (see elaboration below).
Fig. 1 Headache score 0-12 h after cilostazol. Median headache
score 0-12 h after cilostazol. Median headache score was 1 on both
days and thus we found no difference between the two
treatment days
Fig. 2 Headache score after treatment. Headache score 0 h, 2 h and
4 h after treatment with placebo and sumatriptan. There was no
difference in headache score at any time-point between the two
treatment days
Fig. 3 Peak headache score. Difference in median peak headache
score on the two treatment days was not statistical significant
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The headache inducing properties of cilostazol in healthy
volunteers
It has previously been described that cilostazol induces a
headache with migraine characteristics in healthy volun-
teers and a migraine-like attack in migraine patients [2,
8]. More and more studies are using cilostazol headache
models to study the pathophysiology of migraine. Never-
theless, the headache inducing property of cilostazol
differs depending on study design.
Our own group has completed 3 such studies: Birk et al.
conducted a double-blind randomized placebo-controlled
crossover study in which the participant received cilosta-
zol on 1 day and placebo on the other day. The partici-
pants were not offered any treatment as part of the study.
Cilostazol induced a median peak headache score of 3.5
on NRS.
In a previous study by the present authors, cilostazol
induced headache, once established, was treated with
sumatriptan and placebo in a double-blind crossover
study. Treatment was then given on both study days.
Median peak headache score was 2 on the sumatriptan
day and 3 on the placebo day. Hence, when the partici-
pants receive treatment for the headache (including
placebo) we see a milder headache score than if no treat-
ment is offered.
In keeping with that result, the present study where
sumatriptan and placebo were given as pretreatment
found, median peak headache score of only 1.5 on the
sumatriptan day and 2 on the placebo day. When treat-
ment is administered before the headache inducing
substance, the placebo effect may thus be even bigger. It
is interesting, that the placebo effect seems to be present
in experimental headache induction studies to a degree
similar to spontaneous migraine attacks.
Can we use the present model for drug testing?
We suggest that the cilostazol pre-treatment model is
valuable for experimental headache research and per-
haps for novel drug testing, but the model needs some
modifications. It could for an example be interesting to
conduct the present study on migraine patients, who are
known to develop more headache from cilostazol than
healthy volunteers.
Conclusion
This study shows that pre-treatment with sumatriptan
prevents cilostazol induced headache from developing.
However, the placebo group did not develop enough
headache to get statistically significant results. We also
show by comparison to previous studies that the placebo
effect on experimental headache is considerable and
should be taken into consideration in future power
calculations.
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